SEC Form 4 · accession 0001213900-26-077564
MoonLake Immunotherapeutics · MLTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
da Silva Jorge Santos
Officer — Chief Executive Officer · Director
Period of report
Jul 9, 2026
Accepted (ET)
Jul 13, 2026 · 4:10 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001821586
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Class A ordinary shares, par value $0.0001 per shareF2 | Jul 9, 2026 | S | 33,936 | $20.01 | D | 2,843,182 | D | |
| Class A ordinary shares, par value $0.0001 per shareF3 | Jul 10, 2026 | S | 68,289 | $20.02 | D | 2,774,893 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026.
- F2The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $20.00 to $20.03. Upon request by the staff of the U.S. Securities and Exchange Commission (the "SEC"), the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- F3The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $20.00 to $20.10. Upon request by the staff of the SEC, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.